SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics presented positive clinical data for AlloNK…

Artiva Biotherapeutics, Inc. · PRESS-RELEASE filed Jun 8, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 8, 2026 at 06:30 ET

Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 response at six months in refractory RA patients from its Phase 2a basket trial, and received FDA RMAT designation for AlloNK plus rituximab in refractory RA. The company plans to initiate a Phase 3 registrational trial in 2026, with cash runway extended into 2029 from a recent financing. These developments are bullish for the stock as they de-risk the regulatory path and validate the therapeutic potential in a large autoimmune market.

  • FDA granted RMAT designation to AlloNK plus rituximab for refractory RA, providing expedited development and review benefits.
  • 71% of patients in the company-sponsored Phase 2a basket trial achieved ACR50 response at six months.
  • No CRS, ICANS, AlloNK-related serious adverse events, or treatment discontinuations due to AEs in 55 autoimmune patients.
  • Complete B-cell depletion by Day 13 in all 28 evaluable RA patients using a high-sensitivity assay.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access